Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06712823 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

Study acronym: CALM2-CAH
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 2027 to Jul 2029v5 Show 8 more changesShow less
    • Primary endpoints revised (4)
    • Enrollment target: 150 to 200
    • Study sites: 9 to 13
    • Study completion date: Nov 2027 to Aug 2029
    • Eligibility criteria expanded, about 77 words
    • Secondary endpoints revised (2)
    • Study description revised
    • Study title expanded, about 3 words
  2. Study sites: 3 to 9v4
  3. Study sites: 1 to 3v3
  4. Start date changed from estimate of Nov 2024 to Feb 25, 2025v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).
Trial Details
NCT Number NCT06712823
Lead Sponsor Crinetics Pharmaceuticals Inc.
Conditions
(from sponsor)		 Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Related terms Adrenal Hyperplasia, Congenital
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov